Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 12 Lung Neoplasms 11 Carcinoma, Non-Small-Cell Lung 11 Oropharyngeal Neoplasms 10 Glioblastoma 10 Breast Neoplasms 9 Urinary Bladder Neoplasms 7 Glioma 6 Squamous Cell Carcinoma of Head and Neck 5 Sarcoma 5 Neoplasm Metastasis 5 Mouth Neoplasms 5 Esophageal Neoplasms 5 Carcinoma 5 Burkitt Lymphoma 5 Astrocytoma 5 Uterine Cervical Neoplasms 4 Rhabdomyosarcoma 4 Pancreatic Neoplasms 4 Laryngeal Neoplasms 4 Histiocytoma, Malignant Fibrous 4 Gliosarcoma 4 Carcinoma, Hepatocellular 4 Adenocarcinoma of Lung 4 Triple Negative Breast Neoplasms 3 Stomach Neoplasms 3 Sarcoma, Synovial 3 Rhabdomyosarcoma, Embryonal 3 Rectal Neoplasms 3 Neoplasms 3

Interventions

Cyclophosphamide 25 fludarabine 19 Dexamethasone 17 pembrolizumab 13 Rituximab 12 venetoclax 9 Lenalidomide 9 Gemcitabine 9 Etoposide 9 pomalidomide 8 Vincristine 7 glofitamab 6 fludarabine phosphate 6 carfilzomib 6 Temozolomide 6 obinutuzumab 5 daratumumab 5 Prednisone 5 Nivolumab 5 Doxorubicin 5 Cisplatin 5 Calcium Dobesilate 5 Bortezomib 5 zanubrutinib 4 selinexor 4 Immunotherapy, Adoptive 4 Cytarabine 4 Carboplatin 4 Azacitidine 4 ruxolitinib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Radiation × 90 days × Clear all

NCT03970447 2026-05-15

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting

Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡